Price (delayed)
$1.24
Market cap
$228.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$230.87M
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN
There are no recent dividends present for TVGN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.